BIOTECHNOLOGY

* Palo Alto-based Incyte Pharmaceuticals Inc. shares tumbled 18% amid concern the company will cancel plans to create a separate company to finance its effort to substantially expand its database of research on the human genetic makeup. Incyte shares fell $5 to close at $22.63 on Nasdaq. It was the biggest one-day percentage decline since the company’s initial public offering in November 1993.